Cancer Stem Cell Therapy Market 2021-2028: Analysed by Business Growth, Development Factors and Future Trends || STEMCELL Technologies Inc., Astellas…
stemadminStem Cell ResearchNo comments

Cancer Stem Cell Therapy Market2021 business research report will help to save time as well as add credibility to the work done for growing the business. This business market research report helps stay up-to-date about the whole market and also gives a holistic view of the market. The company profiles of all the key players and brands that are dominating the market with moves like product launches, joint ventures, mergers, and acquisitions which in turn are affecting the sales, import, export, revenue, and CAGR values are mentioned in the report

Read more
Global Stem Cells Market Seeking Excellent Growth by 2027 : Osiris Therapeutics Inc., STEMCELL Technologies Inc., BIOTIME, Inc., Celgene Corporation …
stemadminStem Cell ResearchNo comments

The report on theGlobal Stem Cells Market Research Report Covers, Future Trends, Size, Share, Past, Present Data and Deep Analysis, And Forecast, 2021-2027market documented by Zion Market Research (ZMR) means to offer a coordinated and orderly methodology for the major aspects that have influenced the market in the past and the forthcoming market prospects on which the organizations can depend upon before investing. It furnishes with a reasonable examination of the market for better decision-making and assessment to put resources into it.

Read more
ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP) – Business Wire
stemadminStem Cell ResearchNo comments

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside (NR) healthy aging nutrient. Through the industry-leading ChromaDex External Research Program (CERP), ChromaDex provides its patented NR ingredient, Niagen, technological and scientific expertise to research institutions and universities at no cost.

Read more
HealthLynked Corp. Presents At The World Stem Cell Summit On Thursday, June 17, 2021 At 12:45pm Eastern Standard Time – PRNewswire
stemadminStem Cell ResearchNo comments

NAPLES, Fla., June 16, 2021 /PRNewswire/ -- HealthLynked(OTCQB: HLYK) a global healthcare network focused on care management of its members and a provider of healthcare technologies that connects doctors, patients, and medical data, today announced that its CEO Dr. Michael Dent and CFO George O'Leary will present at the Investor Forum at the World Stem Cell Summit to be held (virtually) June 14-18, 2021 the Company's presentation will be on Thursday, June 17, 2021 at 12:45pm Eastern Standard Time and consist of a 20-minute formal description of the Company and its financial position, followed by a 20-minute Q&A session moderated by a Noble Capital Markets equity research representative. The presentation can be accessed in two ways: by registering for the full World Stem Cell Summitwww.worldstemcellsummit.com,or by registering (at no cost) for the Investor Forum only atwww.channelchek.com;the investor portal created by Noble.

Read more
Purdue prof discovers stem cells that could help treat muscular disorders – Indianapolis Business Journal
stemadminStem Cell ResearchNo comments

Purdue animal science professor Shihuan Kuang has discovered a new subset of stem cells that researchers hope could lead to more knowledge about muscular diseases and possible treatments for disorders such as muscular dystrophy. With the help of a $2.3 million grant from the National Institutes of Healths National Institute of Arthritis and Musculoskeletal and Skin Diseases, Kuangs research will continue in an effort to better understand the origin and function of these stem cells, which Kuang has named immunomyoblasts. Such knowledge will inform specific strategies to effectively target this cell population to boost the bodys ability to regenerate injured muscles, Kuang said

Read more
Heartseed collects new venture round after $598M heart failure stem cell deal with Novo Nordisk – FierceBiotech
stemadminStem Cell ResearchNo comments

To continue developing its stem-cell based treatment for heart failure, Tokyo-based Heartseed has raised 4 billion yen, or about $37 million U.S., in its latest venture capital round. The funding will help kickstart a global clinical trial of its lead therapy, which aims to sow the weakened areas of the hearts ventricles with fresh, purified cardiac muscle tissue, built from induced pluripotent stem cells

Read more

Theme: Illdy.